Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/10495/29526
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Cienfuegos Gallet, Astrid Vanessa | - |
dc.contributor.author | Ocampo de Los Ríos, Ana María | - |
dc.contributor.author | Sierra Viana, Patricia María | - |
dc.contributor.author | Ramírez Brinez, Faiver | - |
dc.contributor.author | Restrepo Castro, Carlos Andrés | - |
dc.contributor.author | Roncancio Villamil, Gustavo | - |
dc.contributor.author | Corral Londoño, Helena del | - |
dc.contributor.author | Jiménez Quiceno, Judy Natalia | - |
dc.date.accessioned | 2022-06-30T22:01:17Z | - |
dc.date.available | 2022-06-30T22:01:17Z | - |
dc.date.issued | 2019 | - |
dc.identifier.uri | http://hdl.handle.net/10495/29526 | - |
dc.description.abstract | ABSTRACT : Background: Many gaps in the burden of resistant pathogens exist in endemic areas of low- and middle-income economies, especially those endemic for carbapenem resistance. The aim of this study is to evaluate risk factors for carbapenem-resistance, to estimate the association between carbapenem-resistance and all-cause 30-day mortality and to examine whether mortality is mediated by inappropriate therapy. Methods: A case-control and a cohort study were conducted in one tertiary-care hospital in Medellín, Colombia from 2014 to 2015. Phenotypic and genotypic characterization of isolates was performed. In the case-control study, cases were defined as patients infected with carbapenem-resistant K. pneumoniae (CRKP) and controls as patients infected with carbapenem-susceptible K. pneumoniae (CSKP). A risk factor analysis was conducted using logistic regression models. In the cohort study, the exposed group was defined as patients infected with CRKP and the non-exposed group as patients infected with CSKP. A survival analysis using an accelerated failure time model with a lognormal distribution was performed to estimate the association between carbapenem resistance and all-cause 30-day-mortality and to examine whether mortality is mediated by inappropriate therapy. Results: A total of 338 patients were enrolled; 49 were infected with CRKP and 289 with CSKP. Among CRKP isolates CG258 (n = 29), ST25 (n = 5) and ST307 (n = 4) were detected. Of importance, every day of meropenem (OR 1.18, 95%CI 1.10–1.28) and cefepime (OR 1.22, 95%CI 1.03–1.49) use increase the risk of carbapenem resistance. Additional risk factors were previous use of ciprofloxacin (OR 2.37, 95%CI 1.00–5.35) and urinary catheter (OR 2.60, 95%CI 1.25–5.37). Furthermore, a significant lower survival time was estimated for patients infected with CRKP compared to CSKP (Relative Times 0.44, 95%CI 0.24–0.82). The strength of association was reduced when appropriate therapy was included in the model (RT = 0.81 95%CI 0.48–1.37). Conclusion: Short antibiotic courses had the potential to reduce the selection and transmission of CRKP. A high burden in mortality occurred in patients infected with CRKP in a KPC endemic setting and CRKP leads to increased mortality via inappropriate antibiotic treatment. Furthermore, dissemination of recognized hypervirulent clones could add to the list of challenges for antibiotic resistance control. | spa |
dc.format.extent | 13 | spa |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | eng | spa |
dc.publisher | BMC (BioMed Central) | spa |
dc.type.hasversion | info:eu-repo/semantics/publishedVersion | spa |
dc.rights | info:eu-repo/semantics/openAccess | spa |
dc.rights.uri | http://creativecommons.org/licenses/by/2.5/co/ | * |
dc.title | Risk factors and survival of patients infected with carbapenem-resistant Klebsiella pneumoniae in a KPC endemic setting: a case-control and cohort study | spa |
dc.type | info:eu-repo/semantics/article | spa |
dc.publisher.group | Grupo de Investigación en Microbiología Básica y Aplicada-Microba | spa |
dc.identifier.doi | 10.1186/s12879-019-4461-x | - |
oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 | spa |
dc.rights.accessrights | http://purl.org/coar/access_right/c_abf2 | spa |
dc.identifier.eissn | 1471-2334 | - |
oaire.citationtitle | BMC Infectious Diseases | spa |
oaire.citationstartpage | 1 | spa |
oaire.citationendpage | 13 | spa |
oaire.citationvolume | 19 | spa |
oaire.citationissue | 830 | spa |
dc.rights.creativecommons | https://creativecommons.org/licenses/by/4.0/ | spa |
dc.publisher.place | Londres, Inglaterra | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_2df8fbb1 | spa |
dc.type.redcol | https://purl.org/redcol/resource_type/ART | spa |
dc.type.local | Artículo de investigación | spa |
dc.subject.decs | Estudios de Casos y Controles | - |
dc.subject.decs | Case-Control Studies | - |
dc.subject.decs | Estudios de Cohortes | - |
dc.subject.decs | Cohort Studies | - |
dc.subject.decs | Klebsiella pneumoniae | - |
dc.subject.decs | Factores de Riesgo | - |
dc.subject.decs | Risk Factors | - |
dc.subject.decs | Mortalidad | - |
dc.subject.decs | Mortality | - |
dc.subject.decs | Carbapenémicos | - |
dc.subject.decs | Carbapenems | - |
dc.subject.decs | Farmacorresistencia Microbiana | - |
dc.subject.decs | Drug Resistance, Microbial | - |
dc.description.researchgroupid | COL0126131 | spa |
dc.relation.ispartofjournalabbrev | BMC Infect. Dis. | spa |
Aparece en las colecciones: | Artículos de Revista en Microbiología |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
CienfuegosAstrid_2019_RiskFactorsSurvival.pdf | Artículo de investigación | 7.47 MB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons